CALIFORNIA, US. June 4, 2026 – Sapyen and My Surrogacy Journey have entered into a long-term partnership designed to support intended parents with enhanced fertility diagnostics and reproductive care resources. The collaboration combines Sapyen’s expertise in male fertility testing with My Surrogacy Journey’s extensive experience managing international surrogacy journeys, beginning with services across the United States.
Through the partnership, intended parents working with My Surrogacy Journey will gain access to Sapyen’s suite of fertility testing solutions, including semen analysis, DNA fragmentation assessment, and infectious disease screening. Together, the organizations aim to create a more connected and efficient experience for individuals navigating complex reproductive pathways.
The agreement marks the coming together of two organizations focused on addressing long-standing challenges within fertility and surrogacy care.
Historically, fertility testing for men has often involved fragmented processes, in-person clinic visits, and logistical barriers that can delay access to care. For intended parents pursuing surrogacy, these challenges are frequently compounded by the need to coordinate services across multiple regions, providers, and regulatory environments.
Sapyen and My Surrogacy Journey believe future fertility care models will depend on coordinated global systems that allow patients to access services more easily regardless of location.
My Surrogacy Journey has become a respected name within international surrogacy, recognized for its patient-focused approach, commitment to ethical standards, and ability to coordinate complex journeys through a trusted global network.
Sapyen has likewise earned recognition for modernizing fertility diagnostics through technology-enabled testing and preservation solutions that support healthcare organizations, clinics, and laboratories worldwide.
Its proprietary SPX72 technology extends semen sample viability to as much as 72 hours, helping make advanced fertility testing and preservation more accessible outside traditional collection environments.
“The historical fertility model was built around geography,” said Ash Ramachandran, Founder and CEO of Sapyen. “Patients travelled to infrastructure. The next generation of reproductive medicine will invert that entirely.”
The partnership will begin in the United States before expanding into broader fertility and reproductive health initiatives in the future.
“Surrogacy is one of the most operationally complex categories in reproductive medicine,” Ramachandran continued. “It requires coordination across clinicians, laboratories, legal teams, donors, intended parents, and international jurisdictions simultaneously. Infrastructure quality materially impacts patient outcomes in that environment.
“My Surrogacy Journey has built one of the most sophisticated and trusted platforms globally for navigating that complexity. They are not simply facilitating introductions. They are helping define the operational and ethical standard for modern surrogacy internationally.”
Ramachandran noted that fertility diagnostics and preservation are becoming increasingly central to reproductive healthcare rather than supplementary services.
“For decades, fertility testing and preservation were positioned as reactive services. By the time many patients entered the system, optionality had already narrowed. We believe that changes now. Earlier diagnostics, better biological data, and accessible preservation infrastructure will increasingly become standard entry points into reproductive medicine globally.”
Michael Johnson-Ellis, Co-founder and Co-CEO of My Surrogacy Journey, said the partnership aligns with the organization’s commitment to building a comprehensive support ecosystem for intended parents around the world.
“Our responsibility to intended parents extends far beyond guidance. We are building an ecosystem around them capable of supporting extraordinarily complex journeys with consistency, credibility, and care.
“Sapyen immediately distinguished itself with both its scientific credibility and operational capability to execute fertility diagnostics and preservation at international scale.
“Their infrastructure, laboratory integration, and long-term vision for modern fertility care make them an exceptionally strong partner for My Surrogacy Journey and for the families we support across the world.”
Wes Johnson-Ellis, Co-founder and Co-CEO of My Surrogacy Journey, added that increasingly international fertility journeys require solutions that can function seamlessly across borders.
“Intended parents today are navigating fertility across multiple countries and healthcare systems simultaneously. That requires partners capable of operating with precision internationally. This partnership materially strengthens the level of fertility support available to intended parents navigating increasingly global reproductive pathways.”
The agreement further expands Sapyen’s international presence in fertility diagnostics and reproductive preservation, building on its continued growth across IVF clinic networks, laboratory organizations, benefits providers, and reproductive healthcare partners worldwide.
